E J. Sorenson, A J. Windbank, J N. Mandrekar, W R. Bamlet, S H. Appel, C Armon, P E. Barkhaus, P Bosch, K Boylan, W S. David, E Feldman, J Glass, L Gutmann, J Katz, W King, C A. Luciano, L F. McCluskey, S Nash, D S. Newman, R M. Pascuzzi, E Pioro, L J. Sams, S Scelsa, E P. Simpson, S H. Subramony, E Tiryaki, C A. Thornton
Abstract
Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS.
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2026.
All research outputs
#4,537,458
of 34,054,827 outputs
Outputs from Neurology
#7,869
of 26,167 outputs
Outputs of similar age
#23,418
of 243,563 outputs
Outputs of similar age from Neurology
#25
of 105 outputs
Altmetric has tracked 34,054,827 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 26,167 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,563 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.
